Loading organizations...
Loading organizations...
Heart Metabolics is a technology company.
Heart Metabolics develops pharmaceutical therapies for cardio-metabolic diseases, primarily focusing on hypertrophic cardiomyopathy. Its product strategy advances drugs, including those based on Perhexiline Maleate, targeting metabolic pathways central to these conditions. The company aims to create novel treatments for orphan diseases, seeking to improve patient outcomes through precise interventions.
Heart Metabolics Limited was founded in December 2013, with its launch announced from Ireland. The company emerged from the insight that specific metabolic dysfunctions drive cardiovascular diseases. This understanding underpinned a commitment to develop new biopharmaceutical treatments, recognizing significant unmet medical needs within this therapeutic area.
Heart Metabolics serves the healthcare sector by providing drug treatments for patients affected by cardio-metabolic diseases. The company’s vision is to deliver effective pharmaceutical solutions that improve management and prognosis for individuals with hypertrophic cardiomyopathy. It remains dedicated to expanding therapeutic options for challenging cardiac metabolic disorders.
Heart Metabolics has raised $24.0M across 2 funding rounds.
Heart Metabolics has raised $24.0M in total across 2 funding rounds.
# Heart Metabolics: Correcting the Record
Heart Metabolics is not a technology company—it is a biopharmaceutical company focused on developing treatments for cardio-metabolic diseases.[1]
Heart Metabolics Limited is an Irish biotechnology firm dedicated to developing pharmaceutical therapies for rare and serious heart conditions. The company's primary focus is on perhexiline, a drug candidate designed to treat hypertrophic cardiomyopathy (HCM), a hereditary heart disease characterized by abnormal thickening of the heart muscle.[1] The company addresses a critical clinical gap: HCM patients with severe symptoms have limited treatment options, with no FDA-approved drugs specifically designed for this indication.[1] Heart Metabolics obtained orphan drug designation from the FDA for perhexiline as a first-line treatment for moderate-to-severe heart failure due to HCM, positioning the company to serve a niche but underserved patient population.[1]
Heart Metabolics was founded in 2013 and launched publicly in April 2014 with $20 million in Series A financing.[1] The company was led by Peter Milner, M.D., a cardiovascular clinician and serial entrepreneur who previously co-founded CV Therapeutics.[1] The founding investors included venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper), and AshHill—a consortium of high-caliber life sciences investors.[1] The company's strategy centered on accelerating perhexiline through pivotal Phase 3 clinical trials, building on positive Phase 2 data.[1]
According to the most recent available data, Heart Metabolics has been dissolved as of June 2025.[4] The company's lead product, perhexiline maleate, remains listed in its pipeline targeting hypertrophic cardiomyopathy, though the company is no longer actively operating.[4]
Heart Metabolics has raised $24.0M in total across 2 funding rounds.
Heart Metabolics's investors include Seroba Life Sciences, venBio, AshHill Investments, Brandon Capital, Michael Bettess.
Heart Metabolics has raised $24.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $20.0M Series A | Seroba Life Sciences, venBio, AshHill Investments, Brandon Capital | |
| Jan 4, 2013 | $4.0M Series A | AshHill Investments, Michael Bettess |